Pay in 4 interest-free payments of $5.84 Learn more
Ships within 48 hours · Estimated delivery Aug 29 - Sep 3
Long-Term Safety: What We Know and Don't Know What We Know (From TRIUMPH-4 and TRIUMPH-1) Up to 80 weeks of data: Side effects improve significantly after dose escalation (first 16 weeks hardest) No unexpected safety signals in either trial Dysesthesia doesn't worsen over time (stable) Discontinuation rates stabilize (most who stop do so in first 24 weeks) No deaths attributed to retatrutide in any completed trial TRIUMPH-1 104-week extension shows continued weight loss without new safety signals What We Don't Know Yet Longer-term questions (need 25+ years data): Does dysesthesia resolve completely if medication stopped
Total Fat 0 g
During weight loss, we lose not only unhealthy fat, but also beneficial muscle mass
SOURCE Life Time, Inc.
Table 2 outlines the applications of the GHK peptide with larger bioactive peptides such as CyRL-QN15, LL-37, and AW1 across different wound healing models
